Last 7 days
-1.1%
Last 30 days
-10.7%
Last 90 days
-9.0%
Trailing 12 Months
-44.1%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
BGNE | 298.0B | 1.4B | -3.25% | 8.54% | -148.7 | 210.43 | 20.37% | -37.45% |
ABBV | 279.9B | 58.1B | 4.88% | 1.38% | 23.64 | 4.82 | 3.30% | 2.55% |
REGN | 87.7B | 12.2B | 9.61% | 20.63% | 20.21 | 7.2 | -24.26% | -46.28% |
VRTX | 80.8B | 8.9B | 6.80% | 24.91% | 24.32 | 9.05 | 17.91% | 41.84% |
ALNY | 23.5B | 1.0B | -5.53% | 16.05% | -20.81 | 22.69 | 22.88% | -32.64% |
SRPT | 11.5B | 933.0M | 2.93% | 61.85% | -16.28 | 12.27 | 32.93% | -67.99% |
UTHR | 10.1B | 1.9B | -9.77% | 22.96% | 13.92 | 5.23 | 14.88% | 52.86% |
MID-CAP | ||||||||
MDGL | 4.2B | 504.0K | -19.59% | 144.55% | -14.38 | 2.5K | -66.53% | -22.12% |
RARE | 2.6B | 363.3M | -18.37% | -45.49% | -3.74 | 7.28 | 3.39% | -55.81% |
BPMC | 2.6B | 204.0M | 1.49% | -34.21% | -4.68 | 12.78 | 13.30% | 13.44% |
MRTX | 2.3B | 12.4M | -15.06% | -52.42% | -3.05 | 181.9 | - | -27.34% |
SMALL-CAP | ||||||||
CPRX | 1.7B | 214.2M | 4.81% | 93.98% | 20.42 | 7.92 | 52.10% | 110.42% |
MGNX | 412.2M | 151.9M | 1.98% | -27.23% | -3.44 | 2.71 | 96.19% | 40.75% |
CRBP | 28.6M | - | 145.52% | 1270.00% | -0.67 | 19.11 | -77.61% | 7.22% |
CYTK | 3.1M | 94.6M | -20.08% | -11.44% | -0.01 | 0.03 | 34.30% | -80.65% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | 26.9% | 51,500,000 | 40,568,000 | 15,476,000 | 12,359,000 | 8,803,000 |
Operating Expenses | -3.0% | 198,420,000 | 204,502,000 | 211,041,000 | 215,211,000 | 205,092,000 |
S&GA Expenses | 3.8% | 45,017,000 | 43,389,000 | 42,438,000 | 41,451,000 | 39,679,000 |
R&D Expenses | -4.8% | 153,403,000 | 161,113,000 | 168,603,000 | 173,760,000 | 165,413,000 |
EBITDA | - | -19,845,000 | - | - | - | - |
EBITDA Margin | - | -2.25 | - | - | - | - |
EBT Margin | - | -2.47 | - | - | - | - |
Interest Expenses | 8.2% | 755,000 | 698,000 | 684,000 | 684,000 | 1,092,000 |
Net Income | 11.4% | -146,661,000 | -165,479,000 | -198,497,000 | -203,674,000 | -196,115,000 |
Net Income Margin | 30.2% | -2.85 | -4.08 | -12.83 | - | - |
Free Cahsflow | -17.5% | -175,800,000 | -149,627,000 | -146,531,000 | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -12.9% | 294 | 337 | 342 | 393 | 435 |
Current Assets | -15.4% | 247 | 292 | 327 | 379 | 421 |
Cash Equivalents | -16.2% | 238 | 283 | 320 | 370 | 414 |
Net PPE | 26.8% | 11.00 | 9.00 | 8.00 | 6.00 | 5.00 |
Liabilities | -11.0% | 148 | 166 | 157 | 165 | 175 |
Current Liabilities | -18.2% | 76.00 | 93.00 | 107 | 100 | 118 |
Long Term Debt | -13.1% | 13.00 | 15.00 | 15.00 | 15.00 | 15.00 |
LT Debt, Current | 2.5% | 28.00 | 27.00 | 24.00 | 22.00 | - |
LT Debt, Non Current | -10.4% | 32.00 | 36.00 | 39.00 | 41.00 | 42.00 |
Shareholder's Equity | -14.7% | 146 | 171 | 185 | 228 | 259 |
Retained Earnings | -8.4% | -455 | -420 | -398 | -347 | -308 |
Additional Paid-In Capital | 1.7% | 601 | 591 | 583 | 576 | 568 |
Accumulated Depreciation | 8.7% | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 |
Shares Outstanding | 0.2% | 26.00 | 26.00 | 26.00 | 26.00 | 26.00 |
Cashflow (Last 12 Months) | (In Thousands) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -17.8% | -170,763 | -145,010 | -141,132 | -135,043 | -99,178 |
Share Based Compensation | 8.8% | 31,599 | 29,033 | 29,299 | 28,915 | 24,223 |
Cashflow From Investing | -9.1% | -5,037 | -4,617 | -5,399 | -3,406 | -2,985 |
Cashflow From Financing | -126.2% | -397 | 1,515 | 1,340 | 48,016 | 210,987 |
100%
100%
92.3%
Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.
-7.3%
22.2%
0.8%
FIve years rolling returns for Arcturus Therapeutics Holdings.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-02-21 | MACQUARIE GROUP LTD | sold off | - | -4,000 | - | -% |
2023-02-15 | JANE STREET GROUP, LLC | added | 174 | 986,401 | 1,447,400 | -% |
2023-02-15 | Point72 Middle East FZE | new | - | 79,254 | 79,254 | -% |
2023-02-15 | UNITED CAPITAL FINANCIAL ADVISERS, LLC | sold off | -100 | -370,000 | - | -% |
2023-02-15 | Financial Gravity Asset Management, Inc. | new | - | 32.00 | 32.00 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | 2,642 | 23,642 | -% |
2023-02-15 | MetLife Investment Management, LLC | unchanged | - | 26,066 | 209,066 | -% |
2023-02-15 | SALEM INVESTMENT COUNSELORS INC | unchanged | - | 696 | 1,696 | -% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -7.42 | 7,000 | 140,000 | -% |
2023-02-15 | ALLIANCEBERNSTEIN L.P. | unchanged | - | 48,688 | 386,688 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 5.46% | 1,450,425 | SC 13G | |
Feb 08, 2023 | state street corp | 8.50% | 2,257,846 | SC 13G/A | |
Feb 03, 2023 | sumitomo mitsui trust holdings, inc. | 5.45% | 1,449,060 | SC 13G/A | |
Feb 01, 2023 | federated hermes, inc. | 16.00% | 4,239,554 | SC 13G/A | |
Jan 31, 2023 | blackrock inc. | 7.1% | 1,884,885 | SC 13G/A | |
Apr 11, 2022 | state street corp | 12.20% | 3,217,957 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 5.15% | 1,357,472 | SC 13G | |
Feb 14, 2022 | federated hermes, inc. | 14.02% | 3,694,929 | SC 13G | |
Feb 14, 2022 | price t rowe associates inc /md/ | 0.0% | 15,039 | SC 13G/A | |
Feb 11, 2022 | state street corp | 7.80% | 2,056,074 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 1.35 -91.48% | 1.54 -90.28% | 1.96 -87.63% | 5.02 -68.33% | 8.99 -43.28% |
Current Inflation | 1.34 -91.55% | 1.51 -90.47% | 1.89 -88.08% | 4.54 -71.36% | 7.95 -49.84% |
Very High Inflation | 1.33 -91.61% | 1.48 -90.66% | 1.80 -88.64% | 3.98 -74.89% | 6.75 -57.41% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 17, 2023 | 8-K | Current Report | |
Mar 08, 2023 | 4 | Insider Trading | |
Feb 10, 2023 | SC 13G/A | Major Ownership Report | |
Feb 10, 2023 | SC 13G/A | Major Ownership Report | |
Feb 09, 2023 | SC 13G | Major Ownership Report | |
Feb 08, 2023 | SC 13G/A | Major Ownership Report | |
Feb 03, 2023 | SC 13G/A | Major Ownership Report | |
Feb 01, 2023 | SC 13G/A | Major Ownership Report | |
Jan 31, 2023 | SC 13G/A | Major Ownership Report | |
Dec 30, 2022 | EFFECT | EFFECT |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-06 | Chivukula Pad | sold | -80,350 | 16.07 | -5,000 | chief scientific officer & coo |
2022-12-15 | Marquet Magda | bought | 39,996 | 18.00 | 2,222 | - |
2022-11-23 | Payne Joseph E | bought | 82,550 | 16.51 | 5,000 | president and ceo |
2022-08-15 | SASSINE ANDY | acquired | 19,672 | 18.4195 | 1,068 | chief financial officer |
2022-01-04 | Chivukula Pad | sold | -324,000 | 40.00 | -8,100 | chief scientific officer & coo |
2021-12-16 | Chivukula Pad | sold | -145,328 | 40.0021 | -3,633 | chief scientific officer & coo |
2021-12-08 | Chivukula Pad | sold | -254,680 | 40.00 | -6,367 | chief scientific officer & coo |
2021-11-01 | Chivukula Pad | sold | -444,100 | 44.41 | -10,000 | chief scientific officer & coo |
2021-10-01 | Chivukula Pad | sold | -443,600 | 44.36 | -10,000 | chief scientific officer & coo |
2021-09-01 | Chivukula Pad | sold | -558,600 | 55.86 | -10,000 | chief scientific officer & coo |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Statement of Comprehensive Income [Abstract] | ||||
Revenue | $ 13,369 | $ 2,437 | $ 45,706 | $ 6,565 |
Operating expenses: | ||||
Research and development, net | 37,688 | 45,398 | 120,770 | 141,127 |
General and administrative | 12,488 | 10,860 | 34,211 | 30,645 |
Total operating expenses | 50,176 | 56,258 | 154,981 | 171,772 |
Loss from operations | (36,807) | (53,821) | (109,275) | (165,207) |
Gain (loss) from equity-method investment | (250) | (515) | 670 | |
Gain from foreign currency | 1,862 | 506 | 3,237 | 923 |
Finance expense, net | (321) | (519) | (1,445) | (1,397) |
Net loss | $ (35,266) | $ (54,084) | $ (107,998) | $ (165,011) |
Net loss per share, basic | $ (1.33) | $ (2.05) | $ (4.09) | $ (6.27) |
Net loss per share, diluted | $ (1.33) | $ (2.05) | $ (4.09) | $ (6.27) |
Weighted-average shares outstanding, basic | 26,467 | 26,338 | 26,423 | 26,302 |
Weighted-average shares outstanding, diluted | 26,467 | 26,338 | 26,423 | 26,302 |
Comprehensive loss: | ||||
Net loss | $ (35,266) | $ (54,084) | $ (107,998) | $ (165,011) |
Comprehensive loss | $ (35,266) | $ (54,084) | $ (107,998) | $ (165,011) |
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 237,676 | $ 370,492 |
Accounts receivable | 2,044 | 3,367 |
Prepaid expenses and other current assets | 6,960 | 5,102 |
Total current assets | 246,680 | 378,961 |
Property and equipment, net | 11,347 | 5,643 |
Operating lease right-of-use asset, net | 33,519 | 5,618 |
Equity-method investment | 515 | |
Non-current restricted cash | 2,081 | 2,077 |
Total assets | 293,627 | 392,814 |
Current liabilities: | ||
Accounts payable | 17,962 | 10,058 |
Accrued liabilities | 25,529 | 23,523 |
Current portion of long-term debt | 27,702 | 22,474 |
Deferred revenue | 4,656 | 43,482 |
Total current liabilities | 75,849 | 99,537 |
Deferred revenue, net of current portion | 5,179 | 19,931 |
Long-term debt, net of current portion | 32,038 | 40,633 |
Operating lease liability, net of current portion | 31,218 | 4,502 |
Other non-current liabilities | 3,676 | |
Total liabilities | 147,960 | 164,603 |
Stockholders’ equity | ||
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,492 at September 30, 2022 and 26,372 at December 31, 2021 | 26 | 26 |
Additional paid-in capital | 601,129 | 575,675 |
Accumulated deficit | (455,488) | (347,490) |
Total stockholders’ equity | 145,667 | 228,211 |
Total liabilities and stockholders’ equity | $ 293,627 | $ 392,814 |